CT衍生肿瘤细胞外容积分数预测非肌层浸润性膀胱癌复发
回顾性纳入97例病理确诊的非肌层浸润性膀胱癌患者,治疗前行对比增强CT(含平扫与延迟期),由两名放射科医师独立测量肿瘤细胞外容积分数(ECV)。中位随访38.8个月,复发率34.0%;复发组ECV为35.1±11.4%,高于非复发组的30.7±7.1%(P=0.024),ECV独立预测复发(OR=1.072,95%CI 1.008-1.140,P=0.028),结合性别、肿瘤位置、ECV、切除方式及膀胱内化疗的模型AUC为0.722±0.051,校准良好。
要点
- 复发组肿瘤ECV为35.1±11.4%,高于非复发组的30.7±7.1%(P=0.024)。
- ECV独立预测复发,OR=1.072(95%CI 1.008-1.140,P=0.028)。
- 五变量模型AUC为0.722±0.051,校准良好。
核心结论
- CT衍生ECV是预测非肌层浸润性膀胱癌复发的有前景的影像生物标志物,整合模型提供潜在风险分层并支持个体化临床决策。
研究设计与样本
- 回顾性研究,纳入2017年7月至2022年12月间病理确诊的非肌层浸润性膀胱癌患者97例,均行治疗前对比增强CT(含平扫与延迟期),由两名放射科医师独立测量肿瘤ECV,临床变量取自病历,主要结局为随访期间经膀胱镜或影像确认的肿瘤复发。
诊断标准与关键数值
- 复发组ECV为35.1±11.4%,非复发组为30.7±7.1%(P=0.024);ECV预测复发的OR=1.072(95%CI 1.008-1.140,P=0.028);五变量模型AUC为0.722±0.051;经尿道膀胱肿瘤电切术患者中较高ECV与无复发生存相关(HR=1.031,95%CI 1.002-1.061,P=0.036)。
临床应用与阅片要点
- 原文结论认为CT衍生ECV是预测非肌层浸润性膀胱癌复发的有前景的影像生物标志物,整合模型提供潜在风险分层并支持个体化临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the predictive value of CT-derived tumor extracellular volume fraction (ECV) for recurrence in non-muscle-invasive bladder cancer (NMIBC) and to develop a comprehensive clinical prediction model.
METHODS: This retrospective study included 97 patients with pathologically confirmed NMIBC treated between July 2017 and December 2022. All patients underwent pre-treatment contrast-enhanced CT scans, including unenhanced and delayed phases. Tumor ECV was independently measured by two radiologists. Clinical variables were retrieved from medical records. The primary outcome was tumor recurrence, confirmed by cystoscopy or imaging during follow-up. Univariable analysis identified candidate predictors (P < 0.1), and correlation testing was used to exclude multicollinearity. A logistic regression model was developed using 5-fold stratified cross-validation. Model performance was assessed using the area under the ROC curve (AUC), calibration curves, and recurrence-free survival estimated by Kaplan-Meier analysis.
RESULTS: The recurrence rate was 34.0% over a median follow-up of 38.8 months. ECV values were significantly higher in recurrent cases (35.1 ± 11.4%) than in non-recurrent cases (30.7 ± 7.1%, P = 0.024). ECV independently predicted recurrence (OR = 1.072, 95% CI: 1.008-1.140; P = 0.028). Five variables-gender, tumor location, ECV, resection type, and intravesical chemotherapy-were identified as significant predictors. The model achieved an AUC of 0.722 ± 0.051 with good calibration. Cox proportional hazards regression demonstrated that higher ECV was significantly associated with recurrence-free survival in transurethral resection of bladder tumor patients (HR = 1.031, 95% CI: 1.002-1.061, P = 0.036).
CONCLUSION: CT-derived ECV is a promising imaging biomarker for recurrence prediction in NMIBC. The integrated model provides potential risk stratification and supports personalized clinical decision-making.
引用
- Wang L, Wang Z, Liu Z, et al. CT-derived tumor extracellular volume fraction for predicting recurrence in non-muscle-invasive bladder cancer. Abdom Radiol (NY). 2025. PMID: 41417076. doi:10.1007/s00261-025-05327-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。